Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$7.38 USD
+0.04 (0.54%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $7.32 -0.06 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Kyverna Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 7 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 7 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 62 | 36 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -62 | -29 | 0 | 0 | 0 |
Non-Operating Income | 2 | 1 | NA | NA | NA |
Interest Expense | 0 | 0 | NA | NA | NA |
Pretax Income | -60 | -29 | NA | NA | NA |
Income Taxes | 0 | 0 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -60 | -29 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -60 | -29 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -61 | -28 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | NA | NA | NA |
Income After Depreciation & Amortization | -62 | -29 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.67 | 0.46 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -89.61 | -63.43 | NA | NA | NA |
Diluted Net EPS (GAAP) | -89.61 | -63.43 | NA | NA | NA |
Fiscal Year end for Kyverna Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | NA | NA | 0.00 |
Cost Of Goods | 0.00 | 0.00 | NA | NA | 0.00 |
Gross Profit | 0.00 | 0.00 | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 33.43 | 29.36 | 0.00 | 0.00 | 13.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.43 | -29.36 | 0.00 | 0.00 | -13.31 |
Non-Operating Income | 4.67 | 2.71 | NA | NA | 0.26 |
Interest Expense | 0.04 | 0.04 | NA | NA | 0.05 |
Pretax Income | -28.80 | -26.69 | NA | NA | -13.09 |
Income Taxes | 0.00 | 0.00 | NA | NA | 0.00 |
Minority Interest | 0.00 | 0.00 | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | NA | NA | 0.00 |
Other Income/Charges | 0.00 | 0.00 | NA | NA | 0.00 |
Income From Cont. Operations | -28.80 | -26.69 | NA | NA | -13.09 |
Extras & Discontinued Operations | 0.00 | 0.00 | NA | NA | 0.00 |
Net Income (GAAP) | -28.80 | -26.69 | NA | NA | -13.09 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 43.13 | 23.75 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.67 | -1.12 | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.67 | -1.12 | NA | NA | NA |